Completion of Phase I clinical trial of novel Syk Inhibitor HMPL-523 for autoimmune diseases in ...

(Source: Hutchison China Meditech Limited) London: Friday, 30 October 2015: Hutchison China MediTech Limited ('Chi‑Med') (AIM: HCM) today announces that Hutchison MediPharma Limited ('HMP'), its drug R&D subsidiary, has successfully completed its first-in-human Phase I clinical trial of HMPL‑523. HMPL‑523 is a novel, highly selective and potent small molecule inhibitor targeting spleen tyrosine kinase, also known as Syk, a key component in B-cell receptor signalling. The first-in-human Phase I study of HMPL‑523 was a dose-escalating study conducted to assess the safety, tolerability and pharmacokinetics of both single and repeat doses of HMPL‑523 in healthy volunteers in Australia. The study...